ICCC
Immucell Corp /De/
$10.29
-0.71 (-6.45%)
At close · Jul 2
Market Cap
$93.09M
Shares
9,046,799
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.29
Open$10.38
Day$9.98–10.93
52W$4.52–11.16
Avg vol 30d28K
Short int12K · 0.1% float · 1.0d
Short vol12%
Last earningsApr 8, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+47% above
+
Price vs 50-day avg
+10% above
◦
RSI (14)
58 · neutral
+
MACD trend
positive
+
52-week position
87% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $9 › 200d $7 — 50d above 200d
+
Institutional flow
+4% holders QoQ · +5 funds added
+
Insider flow
Net +$76.0K over 90 days · 0% sells
−
Short interest
0.14% of float · ▲ +35.1% MoM · 1.0 days cover
◦
Volume signal
High volume on a down day — possible exhaustion
◦
Institution breadth
27 holders — mid 3-yr range
Fundamentals
Excellent
+
Revenue growth
+52% Y/Y
+
Gross margin
43%, contracting
+
EPS growth
+54% Y/Y
+
Free cash flow
$1.2M
−
Balance sheet
net debt $5.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 18, 2026
Est · unconfirmed
· in 2 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+47% above
Bullish
Price vs 50-day avg
+10% above
Bullish
RSI (14)
58 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
87% · near high
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +5 funds added
Insider flow
Accumulating
Net +$76.0K over 90 days · 0% sells
Short interest
Rising
0.14% of float · ▲ +35.1% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $5
Now $10 · 87%
52-wk high $11
vs 200-day avg +47%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average manufacturing units per month | 450,000 | Q1 2026 | — |
| average monthly output | 380,000 | the year ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICCC
this stock
Immucell Corp /De/
|
$93.09M | +67.3% | +51.6% | — | 0.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICCC | +4.0% | +2.4% | +56.6% | +2.4% | +67.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +2.6% | +3.6% | +48.6% | +2.7% | +58.1% |